Skip to main content
Premium Trial:

Request an Annual Quote

Affy's Sales Slide 7 Percent in Q1 as Charges Turn Profit to Loss

NEW YORK (GenomeWeb News) — Affymetrix today said first-quarter revenues dropped 7 percent as R&D spending fell 16 and a profit turned to a loss on restructuring charges.
 
Total receipts for the three months ended March 31 fell to $80.4 million from $86.4 million year over year.
 
Product and product-related revenue decreased 10 percent to $71.3 million; royalties and "other" revenue increased 33 percent to $2.4 million; and receipts from Perlegen rose 26 percent to $6.7 million.
 
R&D spending decreased to $19.7 million from $23.5 million.
 
The company said net loss was $4 million, down from a profit of $1.8 million in the year-ago period. Affy said the disparity was the result of $5.4 million in restructuring charges.
 
Affy said it had around $96.3 million in cash and equivalents and $146.9 million in short-term investments as of March 31.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.